TCTC Holdings’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-20,982
| Closed | -$2.14M | – | 464 |
|
|
2023
Q2 | $2.14M | Hold |
20,982
| – | – | 0.09% | 96 |
|
|
2023
Q1 | $1.91M | Hold |
20,982
| – | – | 0.08% | 99 |
|
|
2022
Q4 | $797K | Hold |
20,982
| – | – | 0.03% | 122 |
|
|
2022
Q3 | $527K | Hold |
20,982
| – | – | 0.02% | 129 |
|
|
2022
Q2 | $638K | Hold |
20,982
| – | – | 0.03% | 128 |
|
|
2022
Q1 | $687K | Sell |
20,982
-60
| -0.3% | -$1.78K | 0.03% | 131 |
|
|
2021
Q4 | $555K | Buy |
21,042
+60
| +0.3% | +$4.64K | 0.02% | 135 |
|
|
2021
Q3 | $2.11M | Hold |
20,982
| – | – | 0.1% | 92 |
|
|
2021
Q2 | $2.97M | Hold |
20,982
| – | – | 0.14% | 85 |
|
|
2021
Q1 | $2.09M | Hold |
20,982
| – | – | 0.1% | 86 |
|
|
2020
Q4 | $2.59M | Hold |
20,982
| – | – | 0.14% | 83 |
|
|
2020
Q3 | $2.04M | Hold |
20,982
| – | – | 0.13% | 84 |
|
|
2020
Q2 | $3.27M | Hold |
20,982
| – | – | 0.19% | 78 |
|
|
2020
Q1 | $3.03M | Hold |
20,982
| – | – | 0.23% | 70 |
|
|
2019
Q4 | $4.29M | Hold |
20,982
| – | – | 0.22% | 69 |
|
|
2019
Q3 | $1.69M | Hold |
20,982
| – | – | 0.09% | 84 |
|
|
2019
Q2 | $1.98M | Hold |
20,982
| – | – | 0.11% | 79 |
|
|
2019
Q1 | $1.79M | Hold |
20,982
| – | – | 0.1% | 82 |
|
|
2018
Q4 | $1.18M | Hold |
20,982
| – | – | 0.07% | 87 |
|
|
2018
Q3 | $1.72M | Hold |
20,982
| – | – | 0.08% | 82 |
|
|
2018
Q2 | $734K | Hold |
20,982
| – | – | 0.04% | 102 |
|
|
2018
Q1 | $430K | Hold |
20,982
| – | – | 0.02% | 118 |
|
|
2017
Q4 | $594K | Hold |
20,982
| – | – | 0.03% | 106 |
|
|
2017
Q3 | $653K | Hold |
20,982
| – | – | 0.04% | 101 |
|
|
2017
Q2 | $664K | Hold |
20,982
| – | – | 0.05% | 101 |
|
|
2017
Q1 | $475K | Buy |
+20,982
| New | +$518K | 0.03% | 128 |
|
Other funds holding RETA
TCTC Holdings's RETA Position: Q3 2023 in Review
TCTC Holdings sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 20,982 shares — an estimated $2.14M sold.
TCTC Holdings first reported a position in RETA in Q1 2017 and held it in 26 quarters. The position peaked at $4.29M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- TCTC Holdings reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- TCTC Holdings sold 20,982 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.14M.
- TCTC Holdings first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2017 and held it in 26 quarters.
- TCTC Holdings's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.29M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on TCTC Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.